Amplifica
Amplifica is a clinical-stage biopharmaceutical company developing nature-inspired signaling-molecule treatments for androgenetic alopecia in men and women. Founded in 2022 in San Diego, its pipeline includes AMP-303, AMP-506, AMP-203, and AMP-601 (licensed from the University of California).
- Company typePrivate
- Founded2022
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Amplifica does
Amplifica is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in San Diego, California. It is developing nature-inspired signaling-molecule-based therapeutics for androgenetic alopecia (pattern hair loss), with a pipeline of multiple candidates including lead asset AMP-303, plus AMP-506, AMP-203, and AMP-601 (formerly SCUBE3), the latter in-licensed from the University of California. AMP-303 has completed first-in-human clinical trials with positive results announced in September 2024, with data subsequently presented at the Society for Investigative Dermatology Annual Meeting in May 2025.
The company's underlying scientific premise is the use of signaling molecules (including SCUBE3-derived biology) to reactivate dormant hair follicle activity in both men and women, with potential applicability to hair transplant patients as well. The scientific co-founder, Dr. Maksim Plikus, has 700+ peer-reviewed publications in Nature, Science, and Cell, and the broader leadership team has prior development and commercialization experience at aesthetics-medicine franchises such as Botox, Juvéderm, and Dysport from Allergan and INAMED.
The business model is a traditional clinical-stage biopharma model: develop and clinically validate pipeline assets, pursue regulatory approval, and ultimately commercialize through physician-mediated channels via dermatologists and hair restoration specialists. The company is pre-revenue, having raised $11.8M in a Series A led by SternAegis Ventures in October 2022, and has not yet generated product revenue or commercial sales.
Amplifica firmographics
Firmographics- Name
- Amplifica
- Legal name
- Amplifica Holdings Group, Inc.
- Website
- https://amplificabio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Amplifica is a clinical-stage biopharmaceutical company developing nature-inspired signaling-molecule treatments for androgenetic alopecia in men and women. Founded in 2022 in San Diego, its pipeline includes AMP-303, AMP-506, AMP-203, and AMP-601 (licensed from the University of California).
- Ownership category
- akta.pro rank
Amplifica industry classification
Industry- Product category
- Dermatology Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Pigmentary Disorders (Vitiligo/Melasma) (HLAKACAM)
- akta.pro secondary industry
- Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth) (CRABABAE)
Keywords
Where Amplifica is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Amplifica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: Revenue from commercialization of novel injectable therapeutics for treating androgenetic alopecia. The company is developing AMP-303 as a highly differentiated injectable treatment option that would be administered by physicians, potentially offering superior efficacy compared to daily-use topical and oral therapies.
- Pipeline Product Commercialization: Future revenue from additional pipeline products including AMP-203, AMP-506, and AMP-601 targeting hair loss treatments for men and women.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Amplifica product offering
Product offeringCore offering
Amplifica is a clinical-stage biopharmaceutical company developing novel injectable therapeutics for androgenetic alopecia (hair loss). The company has identified and isolated unique signaling molecules that activate dormant hair follicle stem cells to regrow hair, with lead candidate AMP-303 (a proprietary polysaccharide intradermal injectable) and additional pipeline compounds AMP-506, AMP-203, and AMP-601 (SCUBE3 signaling protein licensed from UC Irvine).
Product overview
Amplifica is a clinical-stage biopharmaceutical company developing a differentiated pipeline of injectable therapeutics for androgenetic alopecia. The core products include AMP-303 (lead candidate, completed first-in-human trials) and AMP-506, which target dormant hair follicle stem cells using proprietary signaling molecules. Additional pipeline compounds include AMP-203 and AMP-601. The company employs a nature-inspired scientific approach, having identified and isolated unique signaling molecules that stimulate hair follicles to regrow natural hair. The portfolio spans from early-stage pre-clinical compounds to late-stage clinical testing, targeting both male and female patients with mechanisms targeting multiple pathways.
Differentiator
Problem solved
Functional benefit
Products and services
- AMP-303 Proprietary intradermal injectable polysaccharide formulation for androgenetic alopecia that stimulates dormant hair follicle stem cells to regrow hair. Completed first-in-human trials demonstrating statistically significant increases in non-vellus hair count (P<0.001) at 60 days post-treatment with durable results through 150 days after a single treatment cycle.
- AMP-506 Lead product candidate in Amplifica's pipeline of proprietary signaling molecules targeting hair follicle regeneration for androgenetic alopecia in male and female patients. Advanced through Series A funding for clinical development.
- AMP-203 Pipeline compound in pre-clinical development targeting androgenetic alopecia through novel mechanisms of action for hair loss treatment.
- AMP-601 Early-stage pipeline compound formerly known as SCUBE3, a multifunctional signaling protein licensed exclusively from the University of California. Currently undergoing pre-clinical testing for hair regrowth applications in androgenetic alopecia.
Quantifiable outcome
- Greater than 15% increase in non-vellus hair count from baseline compared to placebo at 60 days post-treatment (P<0.001)
- +3 more outcomes
Companies that use Amplifica
Customer profileSegments3 records
Ideal customer profiles2 records
Amplifica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Amplifica partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- The Regents of the University of CaliforniacoreAmplifica signed an exclusive license agreement with The Regents of the University of California for a proprietary pipeline product based on SCUBE3 (now referenced as AMP-601), expanding upon research in hair biology. SCUBE3 is a multifunctional signaling protein that serves as nature's potent activator of new hair growth. UCI's Chief Innovation Officer noted this enables ongoing private sector investment to support getting a product to market.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Amplifica competitors and assessment
Company assessmentDirect peers
- Pelage Pharmaceuticals: Clinical-stage biotechnology company developing novel topical therapeutics for androgenetic alopecia. Directly comparable as another early-stage biopharma pursuing differentiated hair-loss treatments through proprietary mechanisms, targeting the same male and female patient populations as Amplifica.
- Aclaris Therapeutics: Clinical-stage biopharmaceutical company developing dermatology therapeutics, including JAK inhibitors and other small molecules for skin and hair conditions. Comparable as a similarly sized dermatology-focused drug developer with multiple pipeline programs and a track record of advancing assets into the clinic.
Emerging players
- Veradermics: Emerging biotechnology company developing novel topical treatments for androgenetic alopecia and other hair-loss conditions. Comparable as an early-stage hair-loss therapeutics developer with a differentiated delivery mechanism, though focused on topical rather than injectable administration.
- Follica: Clinical-stage company developing a treatment regimen for androgenetic alopecia combining scalp disruption (e.g., micro-needling) with a topical pharmaceutical agent. Comparable as a hair-loss-focused biotech pursuing a novel mechanism for stimulating new hair growth through follicle stimulation.
- Stemson Therapeutics: Preclinical-stage regenerative medicine company developing iPSC-derived hair follicle therapies for androgenetic alopecia. Comparable as an emerging hair-loss biotech pursuing a novel biological approach (hair follicle regeneration) to address the same patient population, though at an earlier stage.
Regional players
- Kintor Pharmaceutical: China-based clinical-stage biopharmaceutical company developing KX-826 (pyrilutamide), a topical androgen receptor antagonist for androgenetic alopecia. Comparable as a developer of androgenetic alopecia therapeutics with a novel mechanism targeting the same indication, though primarily serving Asian markets.
Broad incumbents
- Sun Pharma (Cassiopea): Global pharmaceutical company that acquired Cassiopea and markets Breezula (clascoterone) for androgenetic alopecia. Comparable as an established player with an approved/well-advanced androgenetic alopecia therapeutic, representing the type of incumbent Amplifica will compete against at commercialization.
- Pfizer: Global pharmaceutical company that markets LITFULO (ritlecitinib), a JAK inhibitor approved for severe alopecia areata. Comparable as a large incumbent advancing novel mechanisms into the broader hair-loss therapeutic area, and a likely strategic acquirer or partner for differentiated hair-loss assets.
- Eli Lilly: Global pharmaceutical company that markets OLUMIANT (baricitinib), a JAK inhibitor approved for severe alopecia areata. Comparable as a large incumbent with an approved oral hair-loss therapy, representing potential competitive pressure and a strategic acquirer/partner for differentiated injectable hair-loss assets.
Others
- Evolus: Aesthetic-medicine-focused biopharmaceutical company commercializing Jeuveau, a Botox competitor. Comparable as a similarly structured aesthetics-focused biopharma with leadership overlap (Allergan alumni) and a physician-mediated injectable commercial model — useful as a comparable for Amplifica's eventual aesthetic commercialization path.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Amplifica social profiles
Digital presenceAmplifica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Amplifica leadership team
Management profileNumber of profiles
Profiles7 records
Amplifica funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Amplifica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Amplifica
What does Amplifica do?
Amplifica is a clinical-stage biopharmaceutical company developing novel injectable therapeutics for androgenetic alopecia (hair loss). The company has identified and isolated unique signaling molecules that activate dormant hair follicle stem cells to regrow hair, with lead candidate AMP-303 (a proprietary polysaccharide intradermal injectable) and additional pipeline compounds AMP-506, AMP-203, and AMP-601 (SCUBE3 signaling protein licensed from UC Irvine).
Is Amplifica a public or private company?
Amplifica is a private company. It is classified as venture growth investor backed and is currently operating.
When was Amplifica founded?
Amplifica was founded in 2022. It employs 1 to 10 people.
Where is Amplifica based?
Amplifica is headquartered in San Diego, United States, in the North America region.
How does Amplifica make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are pipeline Product Commercialization.
Who are Amplifica's main competitors?
Direct peers on record are Pelage Pharmaceuticals and Aclaris Therapeutics. Emerging players are Veradermics, Follica and Stemson Therapeutics. Kintor Pharmaceutical is listed as a regional player. Broad incumbents are Sun Pharma (Cassiopea), Pfizer and Eli Lilly. Evolus is listed as an others.
Does Amplifica have an API?
No public API is recorded for Amplifica.
What industry is Amplifica in?
Amplifica's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAKACAM, Pigmentary Disorders (Vitiligo/Melasma), with a secondary code of CRABABAE, Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth). Its NAICS code is 325414 and its SIC code is 2836.